Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 10.2% year on year to $181.3 million. The company’s full-year revenue guidance of $723 million at the midpoint came in 2.9% below analysts’ estimates. Its non-GAAP profit of $0.03 per share was in line with analysts’ consensus estimates.
Is now the time to buy NEO? Find out in our full research report (it’s free).
NeoGenomics (NEO) Q2 CY2025 Highlights:
- Revenue: $181.3 million vs analyst estimates of $182.9 million (10.2% year-on-year growth, 0.9% miss)
- Adjusted EPS: $0.03 vs analyst estimates of $0.02 (in line)
- Adjusted EBITDA: $10.68 million vs analyst estimates of $11.31 million (5.9% margin, 5.6% miss)
- The company dropped its revenue guidance for the full year to $723 million at the midpoint from $753 million, a 4% decrease
- Adjusted EPS guidance for the full year is $0.10 at the midpoint, missing analyst estimates by 36.1%
- EBITDA guidance for the full year is $42.5 million at the midpoint, below analyst estimates of $54.7 million
- Operating Margin: -26.3%, down from -13.3% in the same quarter last year
- Market Capitalization: $751.8 million
StockStory’s Take
NeoGenomics’ second quarter was met with a significant negative market reaction, reflecting disappointment over a shortfall in revenue compared to Wall Street expectations and a decrease in full-year guidance. Management attributed the underperformance primarily to ongoing challenges in its pharma services business and a delayed launch of a key new product. CEO Anthony Zook acknowledged, “We missed our revenue guide this quarter. It’s unacceptable. We understand that and take responsibility for it.” The company did highlight solid growth in its core clinical business and continued share gains in high-value testing segments, but external headwinds and internal execution delays weighed on results.
Looking ahead, NeoGenomics’ revised guidance is shaped by persistent uncertainty in the pharmaceutical sector, the ramp-up of new product launches, and efforts to drive operational efficiencies. Management placed particular emphasis on execution risk and the need for transparency in setting realistic expectations, with Zook stating, “Our revised 2025 guidance reflects the headwinds I’ve discussed, while at the same time, acknowledging the efforts we’ve implemented to best position the company for the future.” The company is banking on recently launched products—especially PanTracer liquid biopsy—and enhanced sales force effectiveness to offset pharma headwinds in the second half of the year.
Key Insights from Management’s Remarks
Management attributed the quarter’s underperformance to persistent pharma sector headwinds, a delayed PanTracer launch, and ongoing product mix challenges, while highlighting growth in clinical test volumes and new product development.
- Pharma revenue headwinds: The company faced pronounced weakness in its pharma and biotech customer segment, which management tied to factors such as reduced NIH funding, pricing pressures, and cautious project starts due to industry uncertainty. This resulted in lower-than-expected nonclinical revenue for the quarter.
- PanTracer launch delay: NeoGenomics postponed the commercial launch of its PanTracer liquid biopsy product to incorporate feedback from its early access program, resulting in a three-month delay and a negative impact on both revenue and the targeted NGS growth rate. The product is now launching with enhanced features, including faster turnaround time and broader gene coverage.
- Clinical business momentum: Despite overall softness, the core clinical testing business delivered double-digit organic growth and record test volumes, outpacing broader market growth. Management credited investments in sales force expansion and commercial execution for these gains.
- Portfolio and product mix shifts: Management noted ongoing efforts to refine the test portfolio, with a focus on higher-value areas like therapy selection and minimal residual disease (MRD) testing, while pruning less strategic offerings. NGS (next-generation sequencing) products now account for over 30% of total revenue.
- Operational efficiency initiatives: Investments in laboratory automation, digital pathology, and the integration of laboratory information management systems (LIMS) are expected to improve turnaround times and drive operating leverage in the second half of the year.
Drivers of Future Performance
NeoGenomics expects second-half performance to be shaped by the commercial rollout of new products, continued clinical market share gains, and a cautious outlook for its pharma services segment.
- Pharma segment uncertainty: Management cited persistent challenges in the pharma services business due to market volatility, reduced visibility on clinical trial activity, and competitive pressures. They do not anticipate a near-term recovery in pharma revenues, and have taken a conservative approach to forecasting this segment.
- Product launches and NGS growth: The recent commercial launch of PanTracer liquid biopsy and an expanded NGS portfolio are expected to serve as primary growth drivers for the clinical business. Sales force effectiveness and new customer wins are anticipated to further support volume and share gains.
- Cost discipline and automation: Continued investments in operational efficiency—including automation, digital pathology, and consolidating LIMS—are intended to improve margins and enhance scalability. Management has also responded to pharma revenue weakness by adjusting associated costs and focusing on profitable product lines.
Catalysts in Upcoming Quarters
Looking ahead, key areas to watch include (1) the commercial adoption and revenue impact of the PanTracer liquid biopsy launch, (2) ongoing operational efficiency gains from LIMS integration and automation projects, and (3) signs of stabilization or recovery in the pharma services business. Progress in cross-selling the expanded portfolio to Pathline customers and the outcome of the upcoming MRD-related litigation will also be key drivers to monitor.
NeoGenomics currently trades at $5.84, down from $6.48 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).
Our Favorite Stocks Right Now
Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.
Take advantage of the rebound by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.